Fermentation, isolation and characterization of antibiotic PR-1350

Area of Science:

• Microbiology
• Natural Product Chemistry
• Pharmacology

Background:

• Oidiodendron truncatum is a fungal species with potential for novel compound discovery.
• Antibiotics are crucial for combating bacterial infections and exploring new therapeutic agents.
• Diterpenes represent a diverse class of natural products with varied biological activities.

Purpose of the Study:

• To isolate and characterize a novel antibiotic produced by Oidiodendron truncatum.
• To evaluate the in vitro antibacterial spectrum of the new antibiotic.
• To assess the in vivo anti-cancer activity of the compound against P-388 lymphocytic leukemia.

Main Methods:

• Fermentation of Oidiodendron truncatum strains to produce the antibiotic.
• Isolation and purification of the antibiotic, PR-1350, including its crystalline form PR-1381.
• In vitro susceptibility testing against Gram-positive and Gram-negative bacteria.
• In vivo efficacy studies using a mouse model for P-388 lymphocytic leukemia.
• Biosynthetic analysis using [1-13C]acetate incorporation to determine the compound's structural class.

Main Results:

• A new antibiotic, PR-1350, was successfully isolated from Oidiodendron truncatum.
• PR-1350 demonstrated broad-spectrum inhibition against both Gram-positive and Gram-negative bacteria in vitro.
• The antibiotic exhibited significant activity against P-388 lymphocytic leukemia in mouse models.
• Biosynthetic studies indicated that PR-1350 is a clerodane-type diterpene.

Conclusions:

• Oidiodendron truncatum is a source of a novel antibiotic, PR-1350.
• PR-1350 possesses promising broad-spectrum antibacterial and anti-leukemic properties.
• The compound's clerodane diterpene structure warrants further investigation for therapeutic development.